Experts at AMCP Nexus 2026 said payers are using maximum fair prices (MFPs) as leverage while manufacturers rethink rebate ...
In part 2, Adam Colborn, JD, discussed federal health policy priorities, CMS fraud oversight, and how the midterm elections ...
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight ...
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial ...
Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve ...
One-year open-label MINT data show sustained MG-ADL and QMG score gains with inebilizumab, including in patients who switched from placebo.
An all-oral regimen is a meaningful advance in newly diagnosed AML, yet early monitoring needs, complex dosing, and patient readiness lead many clinicians to begin cycle 1 intravenously.
The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often ...
The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure ...
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results